Arthritis Drugs and New Meds: 2004 Perspectives (cont.)

Remicade (infliximab)

Remicade (infliximab) is an antibody that blocks the effects of tumor necrosis factor alpha (TNF-alpha). TNF-alpha is a substance made by cells of the body that has an important role in promoting inflammation. TNF promotes the inflammation and its associated fever and signs (pain, tenderness, and swelling) in several inflammatory conditions, including rheumatoid arthritis. By blocking the action of TNF-alpha, infliximab reduces the signs and symptoms of inflammation and stops the progression of joint damage. Remicade is used to treat rheumatoid arthritis, Crohn's disease, and other serious forms of inflammation such as uveitis, psoriatic arthritis, and ankylosing spondylitis. Remicade is given by intravenous infusion over approximately 2 hours, usually every 4-8 weeks.

Remicade was effective in treating sarcoidosis of the lungs and Behcet's disease.

Dr. Shiel's Perspective: Other reports of Remicade treatment of sarcoidosis and Behcet's disease are supported by this report. Remicade seems to have beneficial effects in many diseases that feature microscopic areas of tissue inflammation called granulomas. These diseases include Crohn's disease, Wegener's granulomatosis, and sarcoidosis.

Remicade was also reported to increase work productivity and decrease time lost from work in patients with psoriatic arthritis.

Medically Reviewed by a Doctor on 9/16/2015

Health Solutions From Our Sponsors